Fresenius Kabi
Michelle Newton is a seasoned sales leader with extensive experience in the biopharmaceutical and healthcare sectors. Currently serving as the Director of Region Sales for the Southeast Region at Fresenius Kabi since September 2022, Michelle drives the adoption and growth of biosimilars across various therapeutic areas, including Oncology and Rheumatology. Previous roles include positions at MannKind Corporation, where Michelle contributed to the launch of the Afrezza Primary Care Pilot, and AstraZeneca, where transformational leadership resulted in significant sales growth. With a solid educational background holding a Master’s degree in Public Relations from the University of Florida and dual Bachelor's degrees in Business Administration from Old Dominion University, Michelle has consistently demonstrated success in developing sales strategies, mentoring teams, and achieving high-performance metrics throughout a distinguished career spanning over two decades.
This person is not in any teams
This person is not in any offices
Fresenius Kabi
16 followers
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.